Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grass pollen-derived allergy immunotherapeutic - ASIT biotech

Drug Profile

Grass pollen-derived allergy immunotherapeutic - ASIT biotech

Alternative Names: ABT-011; gp-ASIT+™; gpASIT+; Grass-pollen-allergy-immunotherapy-ASIT biotech; Grass-pollen-allergy-vaccine-ASIT biotech; Grass-pollen-extract-ASIT biotech; Oral-grass-pollen-allergy-vaccine-ASIT biotech

Latest Information Update: 13 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioTech Tools
  • Developer ASIT biotech; BioTech Tools
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptides; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Allergic rhinoconjunctivitis

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 05 Nov 2018 Grass pollen-derived allergy immunotherapeutic is available for licensing in USA as of 05 Nov 2018. www.asitbiotech.com 809253616
  • 30 Aug 2018 Phase-III clinical trials in Allergic rhinoconjunctivitis in Hungary (SC) (EudraCT2017-002911-33)
  • 14 Dec 2017 Efficacy data from a phase III trial in Allergic rhinoconjunctivitis released by ASIT biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top